[{"orgOrder":0,"company":"Algernon NeuroScience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon NeuroScience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Algernon NeuroScience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon NeuroScience \/ Inapplicable"},{"orgOrder":0,"company":"Algernon NeuroScience","sponsor":"Dalmore Group","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon NeuroScience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Algernon NeuroScience \/ Dalmore Group","highestDevelopmentStatusID":"6","companyTruncated":"Algernon NeuroScience \/ Dalmore Group"}]

Find Clinical Drug Pipeline Developments & Deals by Algernon NeuroScience

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : AP-188 (N,N-dimethyltryptamine) is a tryptamine, non-selective agonist for 5HT2a receptor and produces hallucinogenic effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin. It is being investigated for ischemic stroke...

                          Product Name : AP-188

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          August 08, 2023

                          Lead Product(s) : Dimethyltryptamine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : The capital raised will be used for research, development, and program management costs related to the completion of the Phase 1 DMT (N, N-dimethyltryptamine) study currently underway as well as Phase 2a stroke and traumatic brain injury (TBI) studies.

                          Product Name : AP-188

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          March 04, 2023

                          Lead Product(s) : Dimethyltryptamine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Dalmore Group

                          Deal Size : $10.0 million

                          Deal Type : Public Offering

                          blank